[A23-140] Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V
Last updated 02.04.2024
Project no.:
A23-140
Commission:
Commission awarded on 21.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with relapsed or refractory diffuse large B-cell lymphoma
Result of dossier assessment:
- after failure of one line of systemic therapy, for whom haematopoietic stem cell transplantation is not an option: added benefit not proven
- after failure of ≥ 2 lines of systemic therapy, for whom CAR-T cell therapy is an option and for whom haematopoietic stem cell transplantation is not an option: added benefit not proven
- after failure of ≥ 2 lines of systemic therapy, for whom CAR-T cell therapy and haematopoietic stem cell transplantation are not an option: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://dx.doi.org/10.60584/A23-140
| Project no. | Title | Status |
|---|---|---|
| G20-01 | Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G22-22 | Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| A23-141 | Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V | Commission completed |